

CONTENTS

Platinum Opinions	<p>The Platinum Hall of Fame e25 http://dx.doi.10.1016/j.eururo.2019.06.007</p>
	<p>Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies 137 <i>L. Trinquart, A. Bill-Axelsson, J.R. Rider</i> Hazard ratios (HRs) are frequently misinterpreted. We describe an easily estimated complementary measure, the difference in restricted mean survival time (RMST), that requires fewer assumptions than the HR and is more readily interpretable. Reporting RMST-based measures may benefit shared decision-making.</p>
Brief Correspondence	<p>Greetings from Africa: The Emergence of Tropical Urological Diseases in Europe. We Had Better Be Prepared! 140 <i>G. Mantica, A. Van der Merwe, G. Bonkat</i> The increasing incidence of tropical urological diseases due to migration represents a challenge for local practitioners. Face-to-face and webinar learning courses could be a simple first step in increasing awareness of this issue.</p>
	<p>Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019 142 <i>G. Gandaglia, P. Albers, P.-A. Abrahamsson, A. Briganti, J.W.F. Catto, C.R. Chapple, F. Montorsi, N. Mottet, M.J. Roobol, J. Sønksen, M. Wirth, H. van Poppel</i> The European Association of Urology supports the implementation of prostate-specific antigen (PSA)-based screening at a population level in Europe. Men at risk of prostate cancer should have a baseline PSA blood test (eg, at 45 yr). This, together with family history, ethnicity, and other factors, should be used to determine subsequent follow-up. Magnetic resonance imaging scans and novel biomarkers should be used to determine which men need biopsy and how many cancers should be treated.</p>
<p>Platinum Priorities Brief Correspondence and Original Articles together with the Full Length Editorials</p>  <p>Prostate Cancer</p>	<p>Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma 151 <i>L. Albiges, T. Powles, M. Staehler, K. Bensalah, R.H. Giles, M. Hora, M.A. Kuczyk, T.B. Lam, B. Ljungberg, L. Marconi, A.S. Merseburger, A. Volpe, Y. Abu-Ghanem, S. Dabestani, S. Fernández-Pello, F. Hofmann, T. Kuusk, R. Tahbaz, A. Bex</i> Pembrolizumab plus axitinib are recommended as a new standard of care in all International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups. For treatment-naïve IMDC intermediate- and poor-risk patients, ipilimumab plus nivolumab remains the standard treatment. Sunitinib, pazopanib, and cabozantinib (in IMDC intermediate- and poor-risk disease) are alternative treatment options in patients who cannot receive or tolerate immune checkpoint inhibition in a first-line setting.</p> <p>RNA Splicing of the <i>BHC80</i> Gene Contributes to Neuroendocrine Prostate Cancer Progression 157 <i>Y. Li, N. Xie, R. Chen, A.R. Lee, J. Lovnicki, E.A. Morrison, L. Fazli, Q. Zhang, C.A. Musselman, Y. Wang, J. Huang, M.E. Gleave, C. Collins, X. Dong</i> We report that alternative RNA splicing of the histone demethylase <i>BHC80</i> gene promotes prostate adenocarcinoma progression to treatment-induced neuroendocrine prostate cancer (t-NEPC). Functionally, reprogrammed RNA splice variant of <i>BHC80</i>-2 mediates nonepigenetic actions in cytoplasm, to stimulate multiple tumor-promoting cytokines for t-NEPC development androgen independently.</p>

The Role of Splicing Regulators in the Emergence of Treatment-induced Neuroendocrine Prostate Cancer: The Next Generation of Drug Targets?	167
<i>C.E. Fletcher</i>	
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects	170
<i>P. Isaacsson Velho, F. Qazi, S. Hassan, M.A. Carducci, S.R. Denmeade, M.C. Markowski, D.L. Thorek, T.L. DeWeese, D.Y. Song, P.T. Tran, M.A. Eisenberger, E.S. Antonarakis</i>	
Our study showed that metastatic castrate-resistant prostate cancer patients with bone metastasis and inactivating homologous recombination deficiency (HRD) mutations have a significantly improved alkaline phosphatase (ALP) response and time to ALP progression. These results should motivate prospective validation of the “synthetic lethality” hypothesis between HRD mutations and greater radium-223 activity.	
Synergistic Interactions: Targeted Radiopharmaceuticals and Homologous Recombination Repair Alterations in Prostate Cancer	177
<i>O. Sartor</i>	
The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting	179
<i>M. Wirth, N. Fossati, P. Albers, C. Bangma, M. Brausi, E. Comperat, S. Faithfull, S. Gillissen, B.A. Jerezek-Fossa, K. Mastris, N. Mottet, S.C. Müller, B. Pieters, M.J. Ribal, V. Sangar, I.G. Schoots, V. Smelov, L. Travado, R. Valdagni, S. Wesselmann, T. Wiegel, H. van Poppel</i>	
The European Association of Urology Prostate Cancer Centre Consensus Meeting defined the criteria for the identification of European Prostate Cancer Centres of Excellence in the field of clinics, research, and education. The inclusion of a quality control approach represents the novelty that supports the excellence of these centres.	
Centers of Excellence: What are Realistic Goals?	187
<i>P.C. Albertsen</i>	
End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy	EU★ACME 189
<i>J.C. Reece, D.C. Dangerfield, C.J. Coombs</i>	
The end-to-side somatic-to-autonomic sural nerve grafting technique successfully restored erectile function in 71% of men with erectile dysfunction after radical prostatectomy (RP). This study suggests that this procedure could become a viable frontline treatment modality to restore erectile function in men after RP.	
Somatic to Autonomic Nerve Grafting for the Treatment of Erectile Dysfunction: It Seems to Work, But How?	197
<i>Z.S. Dovey, A.K. Tewari</i>	
Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors	200
<i>Y. Lotan, S.A. Boorjian, J. Zhang, T.J. Bivalacqua, S.P. Porten, T. Wheeler, S.P. Lerner, R. Hutchinson, F. Francis, E. Davicioni, R.S. Svatek, C.-L. Chen, P.C. Black, E.A. Gibb</i>	
Upstaging of bladder cancer from precystectomy clinical stage \leq T2 to non-organ-confined (NOC) pathological stage \geq T3 or N+ at radical cystectomy is common. Molecular subtyping determined that luminal tumors have lower rates of upstaging to NOC disease than nonluminal tumors.	
Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?	207
<i>J.J. Meeks, D.J. McConkey</i>	

Bladder Cancer



<p>Reviews</p> <p></p> <p>Education</p>	<p>Impact of Three-dimensional Printing in Urology: State of the Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group</p> <p><i>G.E. Cacciamani, Z. Okhunov, A.D. Meneses, M.E. Rodriguez-Socarras, J.G. Rivas, F. Porpiglia, E. Liatsikos, D. Veneziano</i></p> <p>Three-dimensional (3D) additive manufacturing profoundly impacted biomedicine. It has been used to pattern cells; replicate tissues or full organs; create surgical replicas for planning, counseling, and training; and build medical device prototypes and prosthetics, and in numerous other biomedical applications. 3D printing showed revolutionary potential for patient counseling, pre- and intraoperative surgical planning, and education in urology. Together with “patient-tailored” presurgical planning, it puts the basis for 3D-bioprinting technology. Although costs and “production times” remain the major concerns, this kind of technology represents a step forward in order to meet patients’ and surgeons’ expectations.</p>	<p>209</p>
<p>Surgery in Motion</p> <p></p>	<p>Evolution of Robot-assisted Partial Nephrectomy: Techniques and Outcomes from the Transatlantic Robotic Nephron-sparing Surgery Study Group</p> <p><i>P. Casale, G. Lughezzani, N. Buffi, A. Larcher, J. Porter, A. Mottrie, on behalf of the ERUS Scientific Working Group</i></p> <p>Robot-assisted partial nephrectomy (RAPN) represents an effective minimally invasive alternative to open partial nephrectomy in the treatment of clinically localized renal tumors. RAPN resulted in optimal outcomes in the majority of individuals despite tumor complexity.</p>	<p>222</p>
<p>Original Articles</p> <p></p> <p>Prostate Cancer</p>	<p>Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom</p> <p><i>D.W. Donnelly, A. Gavin, A. Downing, L. Hounsome, T. Kearney, E. McNair, D. Allan, D.W. Huws, P. Wright, P.J. Selby, P. Kind, E. Watson, R. Wagland, S. Wilding, H. Butcher, R. Mottram, M. Allen, O. McSorley, L. Sharp, M.D. Mason, W.R. Cross, J.W.F. Catto, A.W. Glaser</i></p> <p>Prostate cancer survivors from England report better quality of survival than those from Scotland, Wales, and Northern Ireland, with differences unrelated to treatment type, and patient and disease characteristics. Within England, regional variations in general health and functional outcome also exist.</p>	<p>228</p>
<p>Bladder Cancer</p> <p></p>	<p>Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy</p> <p><i>B. Konety, N. Shore, A.K. Kader, S. Porten, S. Daneshmand, T. Lough, Y. Lotan</i></p> <p>Cxbladder outperformed urine cytology in both delineating patients at a low risk of urothelial carcinoma and identifying those at a high risk.</p>	<p> 238</p>
<p>Kidney Cancer</p> <p></p>	<p>Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses</p> <p><i>J.R. Andrews, T. Atwell, G. Schmit, C.M. Lohse, A.N. Kurup, A. Weisbrod, M.R. Callstrom, J.C. Chevillet, S.A. Boorjian, B.C. Leibovich, R.H. Thompson</i></p> <p>Percutaneous ablation appears to have acceptable results for cT1 renal tumors. With appropriate patient triage, partial nephrectomy and percutaneous ablation can be used to treat cT1 renal masses, although additional follow-up and further study are still needed.</p>	<p> 244</p>
<p>Words of Wisdom</p> <p></p>	<p>Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010–2015</p> <p><i>R.P. Wernitz, S.E. Eggener</i></p> <p>Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer—29-Year Follow-up</p> <p><i>M. Stöckle</i></p> <p>Re: Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial</p> <p><i>A. Minervini, A. Mari, R. Campi, M. Carini</i></p> <p>Re: A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy</p> <p><i>F. Urabe, T. Ochiya, S. Egawa</i></p>	<p>252</p> <p>253</p> <p>253</p> <p>254</p>

Re: Predictors of Long-term Bladder Management in Spinal Cord Injury Patients—Upper Extremity Function May Matter Most 255

S.P. Elliott

Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-invasive Carcinoma of the Bladder: Does Histologic Subtype Matter? 256

M. Moschini, I. Ouzaid, E. Xylinas

Research Letters

Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method 258

A. Bessa, S. Maclennan, D. Enting, R. Bryan, D. Josephs, S. Hughes, S. Amery, M.S. Khan, S. Malde, R. Nair, F. Cahill, H. Wylie, R. Thurairaja, K. Chatterton, N. Kinsella, C. Häggström, M. Van Hemelrijck

Androgen Deprivation Therapy and Salvage Radiotherapy: Are We Missing Something? 260

C. Gonzalez-San Segunda, F. Couñago, A. Gomez-Iturriaga

Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology 261

S. Loeb, M.S. Katz, B. Stork

Letters to the Editor published online

Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4–6 e33

Y. Yang, X. Wei, P. Han

Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4–6 e34

R. Li, P.E. Spiess, S.M. Gilbert, A. Necchi

Re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604–11 e35

S. Taguchi, T. Nakagawa, H. Fukuhara

Reply to Satoru Taguchi, Tohru Nakagawa, and Hiroshi Fukuhara's Letter to the Editor re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604–11 e37

J.E. Gschwend, M. Heck

Re: Jérôme Gas, Stéphane Bart, Philippe Michel, et al. Prevalence of and Predictive Factors for Burnout Among French Urologists in Training. Eur Urol 2019;75:702–3 e38

M.S. Bolat

Should We Really Screen for Genital Variants Before Birth? e39

N. Kalfa, C. Amouroux, F. Fuchs, F. Paris

Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol 2019;76:106–14. Useful Prognostic Information in Prostate Cancer After Radical Prostatectomy Might Not Be Applicable to High-risk Disease e41

P.S. Sierra

Reply to Pablo Sierra's Letter to the Editor re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol 2019;76:106–14 e42

F. Preisser, D. Tilki

Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260–1 e43

J.M. Inarritu, D. Castellani, J.Y.C. Teoh

Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260–1 e45

A. Bessa, S. Maclennan, D. Enting, R. Bryan, C. Häggström, M. Van Hemelrijck

Congress Calendar e47

The illustration on the cover of this issue is taken from the article by Giovanni E. Cacciamani, Zhamshid Okhunov, Aurus Dourado Meneses, Moises Elias Rodriguez-Socarras, Juan Gomez Rivas, Francesco Porpiglia, Evangelos Liatsikos, Domenico Veneziano, Impact of Three-dimensional Printing in Urology: State of the Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group, which is published on pp. 209–221 of this issue.

